Search clinical trials for: DNL747

Total 8 results

Denali Therapeutics Inc.

Completed

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Alzheimer Disease

United States, Netherlands
Sanofi
Denali Therapeutics Inc.

Terminated

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands
Denali Therapeutics Inc.

Recruiting

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers

Healthy Volunteers

New Zealand
Denali Therapeutics Inc.

Active, not recruiting

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

Healthy Volunteers

Netherlands
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Massachusetts General Hospital

Recruiting

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis

United States

3

Subscribe